"The voice for cancer physicians and their patients in Massachusetts."

FDA grants accelerated approval to sacituzumab govitecan-hziy (TRODELVY) for metastatic triple negative breast cancer

23 Apr 2020 10:48 AM | Anonymous

The U.S. Food and Drug Administration granted accelerated approval to sacituzumab govitecan-hziy (TRODELVY, Immunomedics, Inc.) for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease. Read full press release.

© Copyright.  All rights reserved. 

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org

Powered by Wild Apricot Membership Software